Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Takashi Nakada
The Latest Research and Development Into the Antibody–Drug Conjugate, [Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Chemical and Pharmaceutical Bulletin
Medicine
Drug Discovery
Chemistry
Related publications
Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors
Cancer Discovery
Oncology
Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Development of HER2-specific Humanized Antibody Herceptin (Trastuzumab).
Folia Pharmacologica Japonica
Pharmacology
Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer
The Open Breast Cancer Journal
HER2 Loss in HER2-positive Gastric or Gastroesophageal Cancer After Trastuzumab Therapy: Implication for Further Clinical Research
International Journal of Cancer
Cancer Research
Oncology
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer
Biochimica et Biophysica Acta - Reviews on Cancer
Cancer Research
Oncology
Genetics
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
Scientific Reports
Multidisciplinary
